摘要
目的 研究分析头孢噻肟钠舒巴坦钠联合红霉素治疗大叶性肺炎的有效性及安全性。方法 选择2019年7月-2022年6月在本院治疗的大叶性肺炎患儿60例进行研究,按照患儿入院先后顺序分组,对照组为先入院患儿30例,观察组为后入院患儿30例。对照组应用阿莫西林克拉维酸钾+红霉素,观察组应用头孢噻肟钠舒巴坦钠+红霉素治疗,对2组患儿治疗有效性、症状消失及住院时间、炎性因子水平、治疗安全性进行观察比较。结果 观察组治疗总有效率高于对照组,症状消失及住院时间均短于对照组,治疗后炎性因子水平均低于对照组,对比存在显著差异(P<0.05)。对于治疗安全性而言,两组患儿不良反应发生率比较不存在显著差异(P>0.05)。结论 大叶性肺炎患儿应用头孢噻肟钠舒巴坦钠+红霉素治疗的效果更好,有助于加快患儿症状消失,降低患儿炎性因子水平,且安全可靠,值得临床深入研究与推广应用。
Objective To study effect and safety of cefotaxime sodium and sulbactam sodium combined with erythromycin in treatment of lobar pneumonia.Methods The paper chose 60 children with lobar pneumonia in our hospital from July 2019 to June 2022,and divided them into groups according to admission sequence,30 cases admitted first in control group were treated with amoxicillin clavulanic acid potassium+erythromycin,and 30 cases admitted later in observation group with cefotaxime sodium and sulbactam sodium+erythromycin.Curative effect,symptom disappearance,length of stay,inflammatory factor level and curative safety between two groups was observed and compared.Results Total effective rate of treatment in observation group was higher than control group,symptoms disappeared and length of stay was shorter than control group.Levels of inflammatory factors after treatment were lower than control group,there was significant difference in comparison(P<0.05).For treatment safety,incidence of adverse reactions showed no significant difference between two groups(P>0.05).Conclusion Cefotaxime sodium and sulbactam sodium+erythromycin can achieve good effect in treatment of children with lobar pneumonia,speed up disappearance of symptoms,reduce level of inflammatory factors,which is safe and reliable,and is worthy of in-depth clinical research and promotion.
作者
左阳
ZUO Yang(Pediatrics Department,Lianshui County People's Hospital,Lianshui,Jiangsu 223400)
出处
《智慧健康》
2023年第11期189-193,共5页
Smart Healthcare
关键词
大叶性肺炎
头孢噻肟钠舒巴坦钠
红霉素
有效性
安全性
Lobar pneumonia
Cefotaxime sodium and sulbactam sodium
Erythromycin
Effectiveness
Safety
